Anaplasmosis is a zoonotic disease
affecting dogs, cats, livestock, wildlife, and human. It is highly unlikely
that a person will contract anaplasmosis from pets directly, but pets could
bring ticks with the infection into home, posing a risk to the family. If a pet
is diagnosed with anaplasmosis, precautionary measures to reduce the risk of
infection. The disease is known as human granulocytic anaplasmosis (HGA) in
people, canine granulocytic anaplasmosis in dogs, equine granulocytic
anaplasmosis in horses, and tick-borne fever in ruminants.
Favorable government policies for
research and the presence of a large number of players in the global
anaplasmosis treatment market are the key factors driving the growth of the
market during the forecast period.
The frequency of reported cases of
anaplasmosis is highest among people over 40 years of age. A compromised immune
system such as patients undergoing cancer treatments, advanced human
immunodeficiency virus infection, prior organ transplants may increase the risk
of the severe outcome. Individuals working or spending time in known tick
habitats such as the zoo, animal rearing, and farms may be at increased risk
for infection.
Although anaplasmosis infections can occur during any time of the year,
the majority of cases reported to the CDC have an illness onset during the
summer months and peaks in the months of June and July. This period is the
season for the proliferation of nymphal black-legged ticks that bite humans and
may transmit the pathogen.
The Global anaplasmosis
treatment market size is expected to grow at a CAGR of approximately 6.3%
during the forecast period 2017-2023.
Key Players
Some of key the players in the global anaplasmosis
treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme
(France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company
(U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan
Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel),
Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.),
Takeda Pharmaceuticals (Japan), Ciba Vision (Germany) Novopharm (Canada),
and others.
Segmentation
The anaplasmosis treatment market
is segmented on the basis of species, diagnosis, application, treatment, and
end-users.
On the basis of the species, the
market is segmented into Deer tick (Ixodes scapularis), western black-legged
tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis,
the market is segmented into enzyme-linked immunosorbent assay (ELISA),
indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application,
the market is segmented into humans, pets, livestock, wildlife, and
others
On the basis of the treatment,
the market is segmented into antibiotics, vaccines, and others. The antibiotics
can be further classified as doxycycline, tetracyclines, chlortetracycline,
oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the
market is segmented into hospitals & diagnostic centers, academic
institutes, pharmaceutical & biotechnology companies, and others.
Regional Analysis
The global anaplasmosis treatment
market consists of countries namely America, Europe, Asia Pacific, and the
Middle East, and Africa.
The American anaplasmosis
treatment is the largest market across the globe owing to the high investment
in various private and government-funded research, and increased spending on
pharmaceutical industry. This condition is commonly reported from the upper
midwestern and northeastern United States. the black-legged tick (Ixodes
scapularis) is responsible for transmission of A. phagocytophilum in the upper
Midwest and northeastern U.S. These tick species also transmit the agents of
Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover,
the human co-infections with these organisms have occasionally been reported.
Anaplasmosis treatment is now being controlled in North America due to numerous
veterinary control measures such as routine screening and vaccination of
domestic livestock.
European market is projected to
hold the second largest share of the global anaplasmosis treatment market as
due to the eradication of these disease from Europe. Although some clinical
cases of human granulocytic anaplasmosis have been reported in Europe, mostly
from Slovenia, Sweden, and Poland, most cases have occurred in the United
States. According to the U.S. National Library of Medicine, the prevalence of
Ixodes ricinus ticks in Europe is 3% which is as higher than the United States.
The average prevalence rate of A. phagocytophilum infection among humans in
Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle
Eastern region are expected to grow at a faster rate due to the factors such as
the extensive development of health care infrastructure and growing emphasis on
research and development in the healthcare sector.
Browse More
Pharmaceutical Reports @
https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
